Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment

被引:42
作者
Dobosz, Paula [1 ]
Stepien, Maria [2 ,3 ]
Golke, Anna [4 ]
Dzieciatkowski, Tomasz [5 ]
机构
[1] Minist Interior Affairs & Adm Warsaw, Dept Genet & Genom, Cent Clin Hosp, PL-02507 Warsaw, Poland
[2] Med Univ Lublin, Dept Infect Dis, PL-20059 Lublin, Poland
[3] Med Univ Lublin, Dept Sports Med, PL-20059 Lublin, Poland
[4] Warsaw Univ Life Sci, Inst Vet Med, Dept Preclin Sci, PL-02776 Warsaw, Poland
[5] Med Univ Warsaw, Chair & Dept Med Microbiol, PL-02005 Warsaw, Poland
关键词
checkpoint inhibitors; immunotherapy; cancer; tumour microenvironment; immune system; LUNG-CANCER; T-CELLS; PD-1; BLOCKADE; ACQUIRED-RESISTANCE; ANTITUMOR IMMUNITY; CTLA-4; OPEN-LABEL; MECHANISMS; IPILIMUMAB; PATHWAYS;
D O I
10.3390/ijms23052847
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy is a quickly developing type of treatment and the future of therapy in oncology. This paper is a review of recent findings in the field of immunotherapy with an emphasis on immune checkpoint inhibitors. The challenges that immunotherapy might face in near future, such as primary and acquired resistance and the irAEs, are described in this article, as well as the perspectives such as identification of environmental modifiers of immunity and development of anti-cancer vaccines and combined therapies. There are multiple factors that may be responsible for immunoresistance, such as genomic factors, factors related to the immune system cells or to the cancer microenvironment, factors emerging from the host cells, as well as other factors such as advanced age, biological sex, diet, many hormones, existing comorbidities, and the gut microbiome.
引用
收藏
页数:17
相关论文
共 120 条
  • [1] Anti-CD73 therapy impairs tumor angiogenesis
    Allard, Bertrand
    Turcotte, Martin
    Spring, Kathleen
    Pommey, Sandra
    Royal, Isabelle
    Stagg, John
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (06) : 1466 - 1473
  • [2] Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
    An, Mao Mao
    Zou, Zui
    Shen, Hui
    Liu, Ping
    Chen, Meng Li
    Cao, Yong Bing
    Jiang, Yuan Ying
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (08) : 813 - 821
  • [3] In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
    Arlauckas, Sean P.
    Garris, Christopher S.
    Kohler, Rainer H.
    Kitaoka, Maya
    Cuccarese, Michael F.
    Yang, Katherine S.
    Miller, Miles A.
    Carlson, Jonathan C.
    Freeman, Gordon J.
    Anthony, Robert M.
    Weissleder, Ralph
    Pittet, Mikael J.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (389)
  • [4] Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
    Bagaev, Alexander
    Kotlov, Nikita
    Nomie, Krystle
    Svekolkin, Viktor
    Gafurov, Azamat
    Isaeva, Olga
    Osokin, Nikita
    Kozlov, Ivan
    Frenkel, Felix
    Gancharova, Olga
    Almog, Nava
    Tsiper, Maria
    Ataullakhanov, Ravshan
    Fowler, Nathan
    [J]. CANCER CELL, 2021, 39 (06) : 845 - +
  • [5] Mechanisms of Cancer Resistance to Immunotherapy
    Bai, Rilan
    Chen, Naifei
    Li, Lingyu
    Du, Nawen
    Bai, Ling
    Lv, Zheng
    Tian, Huimin
    Cui, Jiuwei
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
    Banna, Giuseppe Luigi
    Cantale, Ornella
    Bersanelli, Melissa
    Del Re, Marzia
    Friedlaender, Alex
    Cortellini, Alessio
    Addeo, Alfredo
    [J]. ONCOLOGY REVIEWS, 2020, 14 (02) : 135 - 143
  • [7] Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors
    Barlesi, Fabrice
    Tomasini, Pascale
    [J]. LANCET ONCOLOGY, 2020, 21 (05) : 607 - 608
  • [8] Beavis PA, 2015, ONCOIMMUNOLOGY, V4
  • [9] Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
    Bedognetti, Davide
    Ceccarelli, Michele
    Galluzzi, Lorenzo
    Lu, Rongze
    Palucka, Karolina
    Samayoa, Josue
    Spranger, Stefani
    Warren, Sarah
    Wong, Kwok-Kin
    Ziv, Elad
    Chowell, Diego
    Coussens, Lisa M.
    De Carvalho, Daniel D.
    DeNardo, David G.
    Galon, Jerome
    Kaufman, Howard L.
    Kirchhoff, Tomas
    Lotze, Michael T.
    Luke, Jason J.
    Minn, Andy J.
    Politi, Katerina
    Shultz, Leonard D.
    Simon, Richard
    Thorsson, Vesteinn
    Weidhaas, Joanne B.
    Ascierto, Maria Libera
    Ascierto, Paolo Antonio
    Barnes, James M.
    Barsan, Valentin
    Bommareddy, Praveen K.
    Bot, Adrian
    Church, Sarah E.
    Ciliberto, Gennaro
    De Maria, Andrea
    Draganov, Dobrin
    Ho, Winson S.
    McGee, Heather M.
    Monette, Anne
    Murphy, Joseph F.
    Nistico, Paola
    Park, Wungki
    Patel, Maulik
    Quigley, Michael
    Radvanyi, Laszlo
    Raftopoulos, Harry
    Rudqvist, Nils-Petter
    Snyder, Alexandra
    Sweis, Randy F.
    Valpione, Sara
    Butterfield, Lisa H.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
    Bhatia, Alka
    Kumar, Yashwant
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (01) : 41 - 62